Millennium Entities Report 1.3% Stake in Caris Life Sciences
Investment firms disclose joint holdings below 5% threshold after briefly exceeding reporting limits.
June 25, 2025
Millennium Entities and Affiliates File 13G Disclosing Caris Life Sciences Investment
Millennium Management and a group of affiliated entities have reported a 1.3% stake in Caris Life Sciences. The disclosure comes after their collective holdings briefly pushed them past the 5% threshold that triggers a regulatory filing. They’ve since scaled back, but the joint Schedule 13G filing outlines their recent position and activity.
The group includes Riverview Group LLC, Millennium Management LLC, Millennium Group Management LLC, and investor Israel A. Englander. Together, they held 3,583,100 shares of Caris Life Sciences’ common stock as of the filing. Riverview separately reported shared authority over just under 3 million shares. In every case, the shares are held with shared—not sole—voting and disposal power.
This kind of joint structure points to an investment strategy that runs through multiple entities with centralized control. Voting and investment discretion sits with Millennium Management and, by extension, Millennium Group Management and Mr. Englander. According to the filing, none of these parties claim control over Caris Life Sciences or intend to influence it.
Although they crossed the 5% mark on June 17, 2025, the group has already dropped below that level by the time of the June 23 submission. That makes the filing a snapshot of a moment when institutional ownership temporarily met reporting thresholds under SEC rules.
All four parties filed together, with Gil Raviv signing on behalf of the corporate entities in his role as Global General Counsel. Mr. Englander submitted his individual certification directly.
Context on Caris Life Sciences and Industry Positioning
Caris Life Sciences operates in the precision medicine space, using molecular science to support oncology treatment decisions. While the filing doesn’t elaborate on the reasons behind the investment or the subsequent reduction in holdings, it does offer a clear view into how institutional capital flows through firms like Caris—especially in sectors with high innovation potential.
Filings like this provide important transparency. They help market participants understand who’s moving in and out of positions, and they offer insight into how major firms manage exposure in dynamic sectors like biotech.
Share
Read More Articles
